


## AR/BRD4 RIPTAC-1

## Chemical Properties

CAS No. :	3083307-42-7
Formula:	C50H54N10O5S
Molecular Weight:	907.09
Storage:	Powder: -20°C for 3 years   In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



## Biological Description

Description	AR/BRD4 RIPTAC-1 (Compound II-5) is an orally active Regulatory-inducible proximity-targeting chimera (RIPTAC). AR/BRD4 RIPTAC-1 induces the formation of a stable ternary complex between the androgen receptor (AR) and BRD4, thereby blocking BRD4 function. AR/BRD4 RIPTAC-1 inhibits the growth and proliferation of tumor cells. AR/BRD4 RIPTAC-1 holds promise for use in prostate cancer research. AR/BRD4 RIPTAC-1 is additionally applicable in molecular oncology research for investigating androgen receptor-epigenetic regulator interactions and for studying proximity-induced protein complex formation mechanisms in tumor-associated transcriptional regulation systems.
Targets(IC50)	Epigenetic Reader Domain,Androgen Receptor
In vitro	Methods: T47D cells were cultured in vitro and treated with AR/BRD4 RIPTAC-1 (Antiproliferative agent-71) for 72 hours, then the half-maximal growth inhibitory concentration GI <sub>50</sub> was determined. Results: AR/BRD4 RIPTAC-1 (Antiproliferative agent-71) inhibited the growth of T47D cells with a GI <sub>50</sub> lower than 0.5 μM [1].
In vivo	Methods: CB17.SCID mice bearing VCaP tumors were orally administrated for 7 consecutive days, and tumor growth was monitored. Results: AR/BRD4 RIPTAC-1 (Antiproliferative agent-71) effectively inhibited tumor proliferation in vivo [1].

## Solubility Information

Solubility	DMSO: 40 mg/mL (44.1 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

### Preparing Stock Solutions

---

	1mg	5mg	10mg
1 mM	1.1024 mL	5.5121 mL	11.0243 mL
5 mM	0.2205 mL	1.1024 mL	2.2049 mL
10 mM	0.1102 mL	0.5512 mL	1.1024 mL
50 mM	0.022 mL	0.1102 mL	0.2205 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Kyle J. Eastman, et al. Heterobifunctional compounds and methods of treating disease. WO2025085738A1. 2025-04-24.

Raina K, et al. Regulated Induced Proximity Targeting Chimeras (RIPTACs): a Novel Heterobifunctional Small Molecule Therapeutic Strategy for Killing Cancer Cells Selectively. bioRxiv. 2023 Jan 2:2023.01.01.522436.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481